CSI glucagon for treatment of congenital hyperinsulinism
Ended Project Grant Awarded Last action
- Award ID
- R44DK105691
- Recipient
-
Xeris Pharmaceuticals, Inc. UEI YAV5AK7VKJ31
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,996,633
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Place of performance
- Illinois, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$76,568 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $754,662 | |
| Amendment | $833,136 | |
| Original award | $485,403 |
Quick answers
Who received award R44DK105691?
R44DK105691 was awarded to Xeris Pharmaceuticals, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on April 1, 2015.
How much is award R44DK105691 worth?
$1,996,633 has been obligated on R44DK105691.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award